Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

NCT05429697 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: SMT-NK inj.+Pembrolizumab
DRUG: Pembrolizumab

Sponsor

SMT bio Co., Ltd.